ChiCTR2600123268 版本V1.0 版本创建时间2026/04/23 11:30:21 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600123268 

最近更新日期:

Date of Last Refreshed on:

2026-04-23 11:30:02 

注册时间:

Date of Registration:

2026-04-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于睡眠脑电特征的老年抑郁症临床分型和认知损伤风险预测研究

Public title:

A Study on Clinical Subtypes of Geriatric Depression and Risk Prediction of Cognitive Impairment Based on Sleep EEG Features

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于睡眠脑电特征的老年抑郁症临床分型和认知损伤风险预测研究

Scientific title:

A Study on Clinical Subtypes of Geriatric Depression and Risk Prediction of Cognitive Impairment Based on Sleep EEG Features

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

方锦 

研究负责人:

孔晓明 

Applicant:

Fang Jin 

Study leader:

Xiaoming Kong 

申请注册联系人电话:

Applicant telephone:

+86 551 6557 6893

研究负责人电话:

Study leader's
telephone:

+86 551 6557 6893

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

fj190325@163.com

研究负责人电子邮件:

Study leader's E-mail:

kxm186@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省合肥市蜀山区黄山路316号

研究负责人通讯地址:

安徽省合肥市蜀山区黄山路316号

Applicant address:

No. 316 Huangshan Road, Shushan District, Hefei City, Anhui Province, China

Study leader's address:

No. 316 Huangshan Road, Shushan District, Hefei City, Anhui Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

合肥市第四人民医院

Applicant's institution:

Hefei Fourth People’s Hospital

研究负责人所在单位:

合肥市第四人民医院

Affiliation of the Leader:

Hefei Fourth People’s Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

HFSY-IRB-YJ-KYXM-KXM(2026-014-001)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

合肥市第四人民医院临床研究伦理审查委员会

Name of the ethic committee:

Hefei Fourth People's Hospital Clinical Research Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-05 00:00:00

伦理委员会联系人:

曹娜娜

Contact Name of the ethic committee:

Nana Cao

伦理委员会联系地址:

安徽省合肥市蜀山区黄山路316号

Contact Address of the ethic committee:

No. 316 Huangshan Road, Shushan District, Hefei City, Anhui Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 551 6361 6193

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

合肥市第四人民医院

Primary sponsor:

Hefei Fourth People’s Hospital

研究实施负责(组长)单位地址:

安徽省合肥市蜀山区黄山路316号合肥市第四人民医院

Primary sponsor's address:

Hefei Fourth People’s Hospital No. 316 Huangshan Road, Shushan District, Hefei City, Anhui Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽省

市(区县):

合肥市

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

合肥市第四人民医院

具体地址:

安徽省合肥市蜀山区黄山路316号合肥市第四人民医院

Institution
hospital:

Hefei Fourth People’s Hospital

Address:

Hefei Fourth People’s Hospital No. 316 Huangshan Road, Shushan District, Hefei City, Anhui Province, China

经费或物资来源:

2025年度合肥市卫生健康科技项目

Source(s) of funding:

2025 Hefei Municipal Health Science and Technology Project

研究疾病:

老年抑郁症  

Target disease:

Late-Life Depression

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

基于全夜多导睡眠监测与睡眠脑电(EEG)客观指标,系统刻画老年抑郁症患者的睡眠脑电特征,建立基于睡眠脑电参数的老年抑郁症临床分型体系,并评估其对认知功能损伤及认知障碍进展风险的预测价值,同时探究经颅时间干涉刺激对老年抑郁患者认知功能损伤的干预作用。  

Objectives of Study:

Based on whole-night polysomnography and objective sleep electroencephalography (EEG) metrics, this study systematically characterizes the sleep EEG features of patients with late-life depression (LLD), establishes a clinical classification system for LLD based on sleep EEG parameters, evaluates its predictive value for cognitive impairment and the risk of cognitive decline progression, and investigates the intervention effects of transcranial temporal interference stimulation on cognitive impairment in elderly patients with depression.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥60岁; 2.符合DSM-5抑郁障碍的诊断标准; 3.能够配合完成全夜睡眠脑电(PSG/EEG)监测及相关评估; 4.具备基本知情能力,自愿签署知情同意书; 5.基线认知评估未达到痴呆诊断标准; 6.能够配合完成MRI检查; 7.同意按研究方案完成随访。

Inclusion criteria

1. Age >= 60 years; 2. Meets the diagnostic criteria for depressive disorder according to the DSM-5; 3. Able to cooperate in completing whole-night sleep EEG (PSG/EEG) monitoring and associated assessments; 4. Possesses the capacity to provide informed consent and voluntarily signs the informed consent form; 5. Baseline cognitive assessment does not meet the diagnostic criteria for dementia; 6. Able to cooperate in completing MRI examination; 7. Agrees to complete follow-up as required by the study protocol.

排除标准:

1.已被临床明确诊断为痴呆(包括阿尔茨海默病、血管性痴呆、路易体痴呆等); 2.明确诊断为轻度认知障碍但五抑郁症状者; 3.影像学提示明显脑萎缩或白质病变(Fazekas分级≥2级); 4.有明确脑血管病史或符合血管性认知障碍诊断标准; 5.合并控制不良的严重躯体疾病; 6.合并严重神经系统疾病(如帕金森病、癫痫、多发性硬化等); 7.近期使用明显影响脑电活动的药物; 8.合并严重原发性睡眠障碍(如重度睡眠呼吸暂停综合征); 9.存在严重听力、视力或沟通障碍,无法完成评估。

Exclusion criteria:

1. Clinically diagnosed with dementia (including Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, etc.); 2. Diagnosed with mild cognitive impairment without depressive symptoms; 3. Imaging findings indicating significant brain atrophy or white matter lesions (Fazekas grade >= 2); 4. Definite history of cerebrovascular disease or meeting diagnostic criteria for vascular cognitive impairment; 5. Comorbid poorly controlled severe physical illness; 6. Comorbid severe neurological disorder (e.g., Parkinson’s disease, epilepsy, multiple sclerosis, etc.); 7. Recent use of medications that significantly affect electroencephalographic activity; 8. Comorbid severe primary sleep disorder (e.g., severe obstructive sleep apnea syndrome); 9. Severe hearing, visual, or communication impairments that preclude completion of assessments.

研究实施时间:

Study execute time:

From 2026-04-01 00:00:00 To 2028-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-01 00:00:00 To 2027-04-30 00:00:00

干预措施:

Interventions:

组别:

无抽搐电休克治疗组

样本量:

75

Group:

Modified electroconvulsive therapy (MECT) group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

经颅时间干涉刺激组

样本量:

75

Group:

Transcranial temporal interference stimulation (TIS) group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽省 

市(区县):

合肥市 

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

合肥市第四人民医院 

单位级别:

三甲 

Institution
hospital:

Hefei Fourth People’s Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

睡眠监测

指标类型:

主要指标

Outcome:

Sleep monitoring

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简易精神状态检查表

指标类型:

次要指标

Outcome:

Mini-Mental State Examination, MMSE

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿抑郁量表

指标类型:

次要指标

Outcome:

Hamilton Depression Rating Scale, HAMD

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿焦虑量表

指标类型:

次要指标

Outcome:

Hamilton Anxiety Rating Scale, HAMA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

蒙特利尔认知评估量表

指标类型:

次要指标

Outcome:

Montreal Cognitive Assessment, MoCA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病例记录表(CRF)收集原始数据,并通过基于互联网的电子数据采集系统(EDC,如ResMan)进行录入、核查与全流程管理,确保数据质量与合规性。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Raw data are collected using Case Record Forms (CRF), and then entered, verified, and managed throughout the entire process via an internet-based Electronic Data Capture (EDC) system (e.g., ResMan), ensuring data quality and compliance.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-23 11:30:02